trending Market Intelligence /marketintelligence/en/news-insights/trending/KoIjz_VmtzJETDL8bXH97A2 content esgSubNav
In This List

AbbVie ordered to pay $140M in 2nd AndroGel lawsuit

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


AbbVie ordered to pay $140M in 2nd AndroGel lawsuit

A federal jury directed AbbVie Inc. to pay more than $140 million in damages to an AndroGel user on claims that the company misrepresented the risks of the drug, Reuters reported Oct. 5.

Jeffrey Konrad claimed that the testosterone replacement drug caused him to suffer a heart attack.

The payment includes $140 million in punitive damages and $140,000 in compensatory damages. The punitive damages seek to deter AbbVie and others from engaging in similar behavior, the news outlet reported, citing Konrad's attorney.

AbbVie said in a statement that it was disappointed with the verdict and plans to appeal, Reuters reported.

The verdict is the second to arise out of about 6,000 pending lawsuits that have been consolidated in federal court in Chicago. Previously, a federal jury found that AbbVie misrepresented the drug's risks and ordered it to pay $150 million in punitive damages.

The cases are part of a series of test trials that seek to help plaintiffs and the drug's manufacturers assess the range of damages and set a legal strategy and settlement options.